OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
July 01, 2019
New guidance documents clarify production standards and processes for developing interchangeable biologic drugs.
Ask the Expert
Cultural and language discrepancies during an audit can be resolved using what many call a “playbook,” says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.
Using a QbD approach from early-stage development through commercialization can ensure that upstream processes are efficient and reliable.
From the Editor
FDA and USP take sides in debate on biologic drug standards.
Real-time monitoring of product- and process-related impurities remains a challenge.
Perspectives on Outsourcing
The increasing growth in the cell- and gene-therapy markets is inspiring CDMOs to expand their services in this emerging biologic drug arena.
FDA guidance is expected to improve industry practices, but work is also needed to bridge disparate industry and software engineering standards.
Although downstream efficiency still lags behind upstream, engineering-driven innovation is breaking through boundaries.
The commercialization of cell and gene therapies has become a reality, prompting deeper considerations of logistics, technology, and design for manufacturing facilities.
In this study, a novel aldo-keto reductase was cloned and purified, and its important conserved sites were analyzed.
Recently released equipment and products include microbioreactor systems, cell therapy automation software, and IIoT-enabled flow sensors.
Click the title above to open the BioPharm International July 2019 issue in an interactive PDF format.